| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prevalence and determinants of troponin T elevation in the general population.
|
Circulation
|
2006
|
2.84
|
|
2
|
Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study.
|
Circulation
|
2005
|
2.47
|
|
3
|
The relationship between C-reactive protein and atherosclerosis differs on the basis of body mass index: the Dallas Heart Study.
|
J Am Coll Cardiol
|
2012
|
2.22
|
|
4
|
Impact of prior coronary artery bypass graft surgery on chronic total occlusion revascularisation: insights from a multicentre US registry.
|
Heart
|
2013
|
1.89
|
|
5
|
Stress myocardial perfusion imaging by CMR provides strong prognostic value to cardiac events regardless of patient's sex.
|
JACC Cardiovasc Imaging
|
2011
|
1.83
|
|
6
|
Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study.
|
Circulation
|
2006
|
1.78
|
|
7
|
The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study.
|
J Am Coll Cardiol
|
2007
|
1.60
|
|
8
|
Temporal trends of fluoroscopy time and contrast utilization in coronary chronic total occlusion revascularization: insights from a multicenter united states registry.
|
Catheter Cardiovasc Interv
|
2014
|
1.48
|
|
9
|
Prevalence and management of coronary chronic total occlusions in a tertiary Veterans Affairs hospital.
|
Catheter Cardiovasc Interv
|
2013
|
1.44
|
|
10
|
Interpretation of Coronary Angiograms Recorded Using Google Glass: A Comparative Analysis.
|
J Invasive Cardiol
|
2015
|
1.39
|
|
11
|
Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study.
|
J Am Coll Cardiol
|
2006
|
1.32
|
|
12
|
Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study.
|
Arterioscler Thromb Vasc Biol
|
2007
|
1.22
|
|
13
|
Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.
|
Diab Vasc Dis Res
|
2009
|
1.16
|
|
14
|
Alpha2cDel322-325 and beta1Arg389 adrenergic polymorphisms are not associated with reduced left ventricular ejection fraction or increased left ventricular volume.
|
J Am Coll Cardiol
|
2006
|
1.00
|
|
15
|
Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart Study).
|
Am J Cardiol
|
2008
|
1.00
|
|
16
|
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.
|
Calcif Tissue Int
|
2010
|
0.93
|
|
17
|
Application of the "hybrid approach" to chronic total occlusion interventions: a detailed procedural analysis.
|
J Interv Cardiol
|
2013
|
0.91
|
|
18
|
Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function.
|
Eur Heart J
|
2010
|
0.89
|
|
19
|
Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals.
|
Circ Heart Fail
|
2013
|
0.85
|
|
20
|
Discordant effects of rosiglitazone on novel inflammatory biomarkers.
|
Am Heart J
|
2013
|
0.83
|
|
21
|
Systematic Review of the BridgePoint System for Crossing Coronary and Peripheral Chronic Total Occlusions.
|
J Invasive Cardiol
|
2015
|
0.79
|
|
22
|
Clinical, angiographic, and procedural predictors of periprocedural complications during chronic total occlusion percutaneous coronary intervention.
|
J Invasive Cardiol
|
2014
|
0.79
|
|
23
|
The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial.
|
Diab Vasc Dis Res
|
2011
|
0.79
|
|
24
|
The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale.
|
Diab Vasc Dis Res
|
2009
|
0.79
|
|
25
|
Effect of glucose-insulin-potassium (GIK) infusion on biomarkers of cardiovascular risk in ST elevation myocardial infarction (STEMI): insight into the failure of GIK.
|
Diab Vasc Dis Res
|
2007
|
0.77
|
|
26
|
Outcomes with first- versus second-generation drug-eluting stents in coronary chronic total occlusions (CTOs): a systematic review and meta-analysis.
|
J Invasive Cardiol
|
2014
|
0.77
|
|
27
|
The AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusion (ACE-CTO) Study.
|
J Invasive Cardiol
|
2015
|
0.77
|
|
28
|
Long-term outcomes with use of the CrossBoss and stingray coronary CTO crossing and re-entry devices.
|
J Invasive Cardiol
|
2013
|
0.77
|
|
29
|
Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment.
|
Diab Vasc Dis Res
|
2011
|
0.77
|
|
30
|
The role of drug-eluting stents for the treatment of coronary chronic total occlusions.
|
Expert Rev Cardiovasc Ther
|
2013
|
0.75
|
|
31
|
Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction.
|
Am J Cardiol
|
2005
|
0.75
|
|
32
|
Comparison of Iodixanol and Ioxaglate for Coronary Optical Coherence Tomography Imaging.
|
J Invasive Cardiol
|
2015
|
0.75
|